Docoh
Loading...

Emerald Health Pharmaceuticals

Filed: 22 Jul 18, 8:00pm
schemaVersion:

1-K: Filer Information

Issuer CIK
0001700800 
Issuer CCC
XXXXXXXX 
Is filer a shell company?Radio button not checked Yes Radio button checked No
Is the electronic copy of an official filing submitted in paper format?Checkbox not checked
File Number
 
Is this filing by a successor company pursuant to Rule 257(b)(5) resulting from a merger or other business combination?Radio button not checked Yes Radio button checked No
Successor File Number
 

Submission Contact Information

Is this a LIVE or TEST Filing?Radio button checked LIVE Radio button not checked TEST
Would you like a Return Copy?Checkbox not checked
Period
12-31-2017 
Name
 
Phone
 
E-Mail Address
 
Notify via Filing Website only?Checkbox not checked

1-K: Tab 1 Notification

This Form 1-K is to provide anRadio button not checked Annual Report Radio button checked Special Financial Report for the fiscal year
Fiscal Year End

12-31-2017 

Exact name of issuer as specified in the issuer's charter

EMERALD HEALTH PHARMACEUTICALS INC. 

CIK

0001700800 

Jurisdiction of Incorporation / Organization

DELAWARE  

I.R.S. Employer Identification Number

82-0669961 

Address of Principal Executive Offices

Address 1

5910 PACIFIC CENTER BLVD. 

Address 2

SUITE 300 

City

SAN DIEGO 

State/Country

CALIFORNIA  

Mailing Zip/ Postal Code

92121 

Phone

858-352-0622 

Title of each class of securities issued pursuant to Regulation A

Common Stock 

1-K: Summary Information Regarding Prior Offering and Proceeds

Summary Information

Checkbox not checkedThe following information must be provided for any Regulation A offering that has terminated or completed prior to the filing of this Form 1-K, unless such information has been previously reported in a manner permissible under Rule 257. If such information has been previously reported, check this box and leave the rest of Part I blank.

Commission File Number of the offering statement

024-10810 

Date of qualification of the offering statement

03-29-2018 

Date of commencement of the offering

03-29-2018 

Amount of securities qualified to be sold in the offering

10000000 

Amount of securities sold in the offering

Price per security

$ 5.0000 

The portion of aggregate sales attributable to securities sold on behalf of the issuer

$ 50000000.00 

The portion of the aggregate sales attributable to securities sold on behalf of selling securityholders

$ 0.00 

Fees in connection with this offering and names of service providers.

Underwriters - Name of Service Provider
N/A
Underwriters - Fees
$ 0.00 
Sales Commissions - Name of Service Provider
N/A
Sales Commissions - Fee
$ 0.00 
Finders' Fees - Name of Service Provider
N/A
Finders' Fees - Fees
$ 0.00 
Accounting or Audit - Name of Service Provider
Deloitte & Touche LLP
Accounting or Audit - Fees
$ 55000.00 
Legal - Name of Service Provider
Morrison & Foerster LLP
Legal - Fees
$ 135000.00 
Promoters - Name of Service Provider
N/A
Promoters - Fees
$ 0.00 
Blue Sky Compliance - Name of Service Provider
N/A
Blue Sky Compliance - Fees
$ 0.00 
CRD Number of any broker or dealer listed

 

Net proceeds to the issuer

$ 49750000.00 

Clarification of responses (if necessary)

The expected fees in connection with this offering total $250,000. The expected fees include the $190,000 listed above as well as an additional $60,000 for other associated fees.